Reno, Nev. (PRWEB) April 17, 2013
First Warning Systems, a Reno-based life sciences software and medical device company, received the 2013 Technology Company of the Year award from Nevada’s Center for Entrepreneurship and Technology (NCET). The award celebrates the northern Nevada individuals and companies who have greatly enhanced the growth and prestige of the technology community.
“This award belongs to my team and this community,” said Matt Benardis, chief operating officer of First Warning Systems. “What a great time to be here and be an entrepreneur in northern Nevada. We are thrilled that we have been recognized for our contribution to early breast cancer detection and look forward to releasing our much needed product to the market shortly.”
First Warning Systems has developed a technology to address challenges in the breast cancer screening market regarding the inaccuracies and shortcomings of current screening technologies. The FWS technology targets the early detection of cellular changes related to the formation of cancer in women with dense breast tissue, where current screening technologies have proven to be ineffective.
“With the surge of states requiring physicians to notify patients that they have dense breast tissue, a solution must evolve to address this at-risk patient population, this condition is more difficult to interpret with standard imaging alternatives and is associated with higher risk for breast cancer,” says First Warning’s CEO, Rob Royea. “FWS has now completed five years of research and development to ensure accurate, reproducible outcomes for breast cancer screening, focusing on mitotic cellular activity and proteomics. As this solution can work on any age and any tissue type, the FWS solution can create significant health management value for women worldwide while providing a protocol for clinicians to manage early onset situations.”
Designed to fit a wearable garment similar to a sports bra, First Warning anticipates bringing their technology to market for an affordable price that will make it widely accessible to all markets.
To learn more, visit http://www.firstwarningsystems.com
About First Warning Systems Process
Temperature readings of breast tissue create a dynamic cell chaos profile using dynamic data which is correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast tissue cells. FWS delivers an objective Clinical Decision Support Service report to the primary care physician with industry leading accuracy.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS’s principal shareholder is Lifeline Biotechnologies, Inc (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities leading to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets. See FWS’ video, “Breast Cancer Tumor Progression” at http://www.firstwarningsystems.com.
Read the full story at http://www.prweb.com/releases/2013/4/prweb10641664.htm.
Copyright©2012 Vocus, Inc.
All rights reserved